[go: up one dir, main page]

FR3103702B1 - Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes - Google Patents

Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes Download PDF

Info

Publication number
FR3103702B1
FR3103702B1 FR1913423A FR1913423A FR3103702B1 FR 3103702 B1 FR3103702 B1 FR 3103702B1 FR 1913423 A FR1913423 A FR 1913423A FR 1913423 A FR1913423 A FR 1913423A FR 3103702 B1 FR3103702 B1 FR 3103702B1
Authority
FR
France
Prior art keywords
prevention
treatment
ankylosing spondylitis
nmn
corresponding compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1913423A
Other languages
English (en)
Other versions
FR3103702A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1913423A priority Critical patent/FR3103702B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to US17/775,615 priority patent/US20230002368A1/en
Priority to CA3160623A priority patent/CA3160623A1/fr
Priority to CN202080077756.XA priority patent/CN114845722A/zh
Priority to EP20811425.6A priority patent/EP4065129A1/fr
Priority to PCT/EP2020/083782 priority patent/WO2021105461A1/fr
Priority to AU2020392623A priority patent/AU2020392623A1/en
Publication of FR3103702A1 publication Critical patent/FR3103702A1/fr
Application granted granted Critical
Publication of FR3103702B1 publication Critical patent/FR3103702B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables, pour son utilisation dans la prévention et/ou le traitement de la spondylarthrite ankylosante ainsi que les compositions le comprenant.
FR1913423A 2019-11-28 2019-11-28 Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes Active FR3103702B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1913423A FR3103702B1 (fr) 2019-11-28 2019-11-28 Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
CA3160623A CA3160623A1 (fr) 2019-11-28 2020-11-27 Utilisation de composes pour la prevention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
CN202080077756.XA CN114845722A (zh) 2019-11-28 2020-11-27 化合物在预防和/或治疗强直性脊柱炎中的应用和相应的组合物
EP20811425.6A EP4065129A1 (fr) 2019-11-28 2020-11-27 Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
US17/775,615 US20230002368A1 (en) 2019-11-28 2020-11-27 Use of compounds for the prevention and/or treatment of ankylosing spondylitis, and corresponding compositions
PCT/EP2020/083782 WO2021105461A1 (fr) 2019-11-28 2020-11-27 Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
AU2020392623A AU2020392623A1 (en) 2019-11-28 2020-11-27 Use of compounds for the prevention and/or treatment of ankylosing spondylitis, and corresponding compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1913423 2019-11-28
FR1913423A FR3103702B1 (fr) 2019-11-28 2019-11-28 Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes

Publications (2)

Publication Number Publication Date
FR3103702A1 FR3103702A1 (fr) 2021-06-04
FR3103702B1 true FR3103702B1 (fr) 2022-02-11

Family

ID=69572232

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1913423A Active FR3103702B1 (fr) 2019-11-28 2019-11-28 Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes

Country Status (7)

Country Link
US (1) US20230002368A1 (fr)
EP (1) EP4065129A1 (fr)
CN (1) CN114845722A (fr)
AU (1) AU2020392623A1 (fr)
CA (1) CA3160623A1 (fr)
FR (1) FR3103702B1 (fr)
WO (1) WO2021105461A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013CN02463A (fr) * 2010-09-03 2015-08-07 Forma Tm Llc
MX342481B (es) * 2010-09-03 2016-09-30 Genentech Inc * Nuevos compuestos y composiciones para la inhibicion de nampt.
BR112013028281A2 (pt) * 2011-05-04 2017-01-10 Forma Tm Llc compostos e composições para inibição de nampt
US20150265642A1 (en) * 2012-10-09 2015-09-24 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
CN106715455A (zh) * 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权（第2 号）有限公司 烟酰胺核苷类似物及其药物组合物和用途
EP3331894B1 (fr) * 2015-08-05 2021-02-17 Metro International Biotech, LLC Dérivés de nicotinamide mononucléotide et leur utilisations

Also Published As

Publication number Publication date
WO2021105461A1 (fr) 2021-06-03
US20230002368A1 (en) 2023-01-05
CA3160623A1 (fr) 2021-06-03
FR3103702A1 (fr) 2021-06-04
EP4065129A1 (fr) 2022-10-05
CN114845722A (zh) 2022-08-02
AU2020392623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
CR20210460A (es) Compuestos útiles en la terapia del vih
PH12019502330A1 (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
MY204185A (en) Composition and methods for the treatment of myopia
MY202884A (en) Compounds useful in hiv therapy
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2021011081A (es) Derivados de nicorandil.
FR3106056B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
FR3103702B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
FR3110836B1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
FR3100449B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210604

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7